Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...

The emergence of antibody-drug conjugates (ADCs) has seen them become a promising class of anticancer therapeutics, exhibiting better precision and reduced off-target toxicity in targeting cancer ...

Pancreatic cancer uses a sugar-coated disguise to evade the immune system, helping explain why it’s so hard to treat.

The updated NCCN Guidelines now include the recommendation for monoclonal antibodies for pre-exposure prophylaxis against COVID-19, highlighting the significance of Invivyd's products in cancer care.

NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in ...

Diffuse Large B-Cell Lymphoma (DLBCL) is a type of blood cancer that that develops from B cell precursors. Healthy B cells produce a broad range of infection-fighting antibodies, making them ...

Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...

—These drugs should be the mainstay of HER2-positive breast cancer treatment, says Melissa McShane, MD, assistant professor and associate program director of the hematology/oncology fellowship ...

As cancer cases climb steadily across India, lower-cost biosimilars like Tishtha could reshape access to life-saving ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of ...